(R)-3-Amino-1-Butanol CAS 61477-40-5 Kemurnian > 99,0% (GC) Dolutegravir Intermediate Factory
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of (R)-3-Amino-1-Butanol (CAS: 61477-40-5) with high quality, commercial production. It's an intermediate of Dolutegravir (CAS: 1051375-16-6). We can provide Certificate of Analysis (COA), worldwide delivery, small and bulk quantities available, strong after-sale service. Please contact: alvin@ruifuchem.com
Jeneng Kimia | (R)-3-Amino-1-Butanol |
sinonim | (R)-3-Aminobutan-1-ol;(3R)-3-Amino-1-Butanol |
Nomer CAS | 61477-40-5 |
Nomer CAT | RF-CC317 |
Status Simpenan | Ing Simpenan, Skala Produksi Nganti Ton |
Formula Molekul | C4H11NO |
Bobot Molekul | 89.14 |
Gravitasi Spesifik (20/20) | 0.95 |
Indeks bias | 1.45 |
Rotasi Spesifik [α]20/D | -12.0° ~ -10.0° (C=1, EtOH) |
Merk | Kimia Ruifu |
Penampilan | Cairan ora ana warna nganti kuning cahya | Cairan Kuning Muda |
Identifikasi dening IR | Sesuai karo Spektrum Standar | Selaras |
Identifikasi dening GC | Selaras karo Wektu Retensi Standar | Selaras |
Kemurnian dening GC (A%) | > 99.0% | 99,8% |
Zat sing gegandhengan | Sembarang Kotoran Tunggal: <0,5% | 0,09% |
Total Kotoran: <1,0% | 0,28% | |
S-Isomer (dening HPLC A%) | <0,10% | 0,02% |
Isi banyu dening KF | <0,50% | 0,10% |
Assay dening GC (w/w%) | > 99.0% | 99,3% |
Paket: Botol Fluorinated, 25kg / Drum, utawa miturut kabutuhan pelanggan
Kondisi panyimpenan:Simpen ing wadhah sing disegel ing papan sing adhem lan garing;Nglindhungi saka cahya lan Kelembapan
(R)-3-Amino-1-Butanol (CAS: 61477-40-5) bisa digunakake minangka perantara ing nyiapake senyawa sing nduweni aktivitas nyandhet integrase HIV.(R)-3-Amino-1-Butanol minangka perantara Dolutegravir (CAS: 1051375-16-6).Dolutegravir (Tivicay) minangka obat anti-ADIS anyar sing dikembangake bebarengan dening raksasa farmasi Inggris GlaxoSmithKline (GSK) karo Perusahaan Farmasi Shionogi Jepang (Shionogi).Ing wulan Agustus 2013, FDA AS nyetujoni dolutegravir (uga diarani S/GSK1349572) kanggo perawatan infeksi HIV-1 ing wong diwasa lan bocah-bocah umur 12 taun lan luwih kanthi kombinasi obat antiretroviral liyane.